October 25 is MDS World Awareness Day. We stand with everyone living with blood cancer — this month and every day.

Publications & Presentations

Advancing scientific understanding from research to real-world evidence.
Every study contributes to a deeper understanding of blood cancer and the potential for new treatment approaches. Through clinical trials, real-world evidence, investigator-sponsored research, and scientific collaboration, Geron is committed to generating evidence that may help advance science, inform clinical practice, and improve outcomes for people living with blood cancer.

Explore our scientific publications and presentations:

This page may contain non-exhaustive scientific information about post-hoc, exploratory, subgroup analyses, or uses that have not yet been approved by regulatory authorities. The information is provided for educational and scientific exchange purposes only, and does not suggest products should be used in a manner not consistent with their respective label approved by the regulatory authorities, which may differ by geography. Any publication reflects the state of knowledge at the time it was published. The information is not medical advice and cannot replace the independent medical judgement of a healthcare professional.

Journal articles

Telomerase Inhibition With Imetelstat in Patients With Lower-Risk Myelodysplastic Syndromes: Integrating Molecular Findings, Cytopenias, and Clinical Outcomes

DGHO

October 9, 2026
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Durable Clinical Outcomes With Imetelstat (IME) in Korean Patients (Pts) With Lower-Risk (LR)-MDS

JSH

October 9, 2026
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Real-World Experience With Imetelstat in Lower-Risk Myelodysplastic Syndromes: Insights From United States Claims Data

JSH

October 9, 2026
Lower-risk Myelodysplastic Syndromes (LR-MDS)Real-World Data

Combining the Telomerase Inhibitor Imetelstat with the BCL-2 Inhibitor Venetoclax Enhances Apoptosis and Improves Survival in Acute Myeloid Leukemia Cellular and Animal Models

Journal of Clinical Medicine

September 23, 2026
Acute Myeloid Leukemia (AML)Preclinical Data

Increased duration of time without transfusion reliance with imetelstat vs placebo in the phase 3 IMerge trial

Blood Neoplasia

April 16, 2026
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Association between treatment-emergent cytopenias and clinical responses to imetelstat in lower-risk myelodysplastic syndromes

Blood Cancer Journal

April 7, 2026
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Clinical outcomes and safety in patients with lower-risk myelodysplastic syndromes treated with imetelstat: Substudy of the phase 3 IMerge trial

British Journal of Haematology

February 1, 2026
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Imetelstat improves patient-reported outcomes and quality of life in lower-risk myelodysplastic syndromes: results from the phase III IMerge study

Haematologica

January 22, 2026
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat

Nature Leukemia

January 12, 2026
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Effect of prior therapy on the clinical activity of imetelstat in patients with transfusion-dependent, ESA-relapsed or -refractory/-ineligible LR-MDS

Blood Cancer Journal

December 31, 2025
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

No Effect of Immunogenicity on Pharmacokinetics, Efficacy, and Safety of the Oligonucleotide Telomerase Inhibitor Imetelstat in Lower-Risk Myelodysplastic Syndromes

Clinical and Translational Science

December 14, 2025
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Plain language summary of IMerge, a Phase 3 studyof imetelstat versus placebo in people with lower-risk myelodysplastic syndromes and anemia

Future Oncology

October 12, 2025
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Conference presentations

Correlation of Patient-Reported Outcomes with Red Blood Cell Transfusion Reduction and Rise in Hemoglobin in Patients with Lower-Risk Myelodysplastic Syndromes in the IMerge Trial

ASH 2024

December 7, 2024
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Advanced Myelodysplastic Neoplasms or AML Failing HMA-based Therapy – Interim Analysis Results of the IMpress Study

ASH 2024

December 7, 2024
Acute Myeloid Leukemia (AML)Clinical Data

Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor in IMpactMF, a Randomized Open Label, Phase 3 Trial

ASH 2024

December 7, 2024
Myelofibrosis (MF)Clinical Data

Overall Survival, Clinical Benefit, and Durable Transfusion Independence with Imetelstat in the IMerge Phase 3 Trial of Red Blood Cell – Transfusion Dependent Lower-Risk Myelodysplastic Syndromes

EHA 2024

June 14, 2024
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Efficacy of imetelstat on red blood cell (RBC)-transfusion independence (TI) in the absence of platelet transfusions or myeloid growth factors in IMerge

ASCO 2024

May 31, 2024
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Novel Nonlinear Population Pharmacokinetic Model of Imetelstat, a First-in-Class Oligonucleotide Telomerase Inhibitor

ASCPT 2024

March 22, 2024
Clinical Data

Clinical Pharmacology of Imetelstat, a First-in-Class Oligonucleotide Telomerase Inhibitor

ASCPT 2024

March 22, 2024
Clinical Data

Patient-Reported Outcomes Among Heavily Pretreated Patients With Lower-Risk Myelodysplastic Syndromes and High Transfusion Burden Treated With Imetelstat in IMerge

Winter Heme 2024

February 2, 2024
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Efficacy of Imetelstat in Achieving Red Blood Cell Transfusion Independence Across Different Risk Subgroups in Patients With Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory to Erythropoiesis-Stimulating Agents in IMerge Phase 3 Study

ASH 2023

December 5, 2023
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Durable Transfusion Independence in Lower-Risk Myelodysplastic Syndrome (LR-MDS) Is Associated With Better Survival: A Population Level Analysis Based on a Large US Health Insurance Claims Database

ASH 2023

December 5, 2023
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Impact of Mutational Status on Clinical Response to Imetelstat in Patients With Lower-Risk Myelodysplastic Syndromes in the IMerge Phase 3 Study

ASH 2023

December 5, 2023
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Durable Continuous Transfusion Independence (TI) With Imetelstat in IMerge Phase 3 for Patients With Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to or Ineligible for Erythropoiesis-Stimulating Agents

ASH 2023

December 5, 2023
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data